null
SMILES Cc1cc(-c2cnn3cc(cnc23)-c2ccc(cc2)C2CCNCC2)c2ccccc2n1
InChI Key InChIKey=UPBPVAZUFAXUAC-UHFFFAOYSA-N
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 12 hits for monomerid = 143566
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 23nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 29nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 125nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 277nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.
US Patent
The Brigham and Women's Hospital, Inc.
US Patent
Affinity DataIC50: 51nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 23nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 29nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 125nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 277nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.
US Patent
The Brigham and Women's Hospital, Inc.
US Patent
Affinity DataIC50: 51nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair